Literature DB >> 781212

Pharmacokinetics of methyldopa in man.

K C Kwan, E L Foltz, G O Breault, J E Baer, J A Totaro.   

Abstract

Single doses of methyldopa were administered orally and intravenously as aqueous solutions to 12 healthy volunteers in a crossover study. Serial plasma and urine samples were analyzed specifically for methyldopa and its O-sulfate conjugate. Kinetic analyses of the results indicated that methyldopa disposition could be adequately represented by a two-compartment open model. Renal excretion accounted for about two-thirds of the plasma clearance of methylodopa. Absorption profiles were constructed with the aid of the pharmacokinetic model and contrasted with estimates of absorption which were model-independent. The mean fraction reaching the systemic circulation as methyldopa was estimated to be 0.25 (range 0.08-0.62 for n = 11). Although most of the absorption occurred within the first 5 hours oral administration, a minor component, suggestive of limited enterohepatic circulation, persisted from 9 to 36 hours. O-sulfate conjugation was route-dependent and appeared to be derived predominantly, if not exclusively, as a first-pass effect of absorption and/or enterophepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 781212

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  18 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Phenylephrine Pharmacokinetics and First-Pass Metabolism: What Is an Ideal Pharmacokinetic Surrogate?

Authors:  Nuggehally R Srinivas
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

Review 3.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

4.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 5.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of methyldopa.

Authors:  E Myhre; H E Rugstad; T Hansen
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

7.  A study of the transfer of alpha-methyldopa to the human foetus and newborn infant.

Authors:  H M Jones; A J Cummings
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  A study of conjugation and drug elimination in the human neonate.

Authors:  A J Cummings; A G Whitelaw
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

9.  Drug metabolism by the gastrointestinal mucosa.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

10.  Duration of effect of single daily dose methyldopa therapy.

Authors:  J M Wright; M Orozco-Gonzalez; G Polak; C T Dollery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.